Latest news and press releases
At BIO International Convention 2026, Mohit Trikha, PhD, CEO of Kiva Bioscience, discussed why emerging human-based preclinical models may have their greatest impact in predicting drug toxicity and tolerability rather than replacing animal testing outright.
At the BIO International Convention 2026, oncology drug development expert Mohit Trikha, PhD, CEO, Kivu Bioscience, discusses the promise and limitations of organoids and other human-based preclinical models, emphasizing the need for stronger validation, cross-functional collaboration, and early regulatory engagement to improve clinical trial success rates.
A conversation between Kivu Bioscience CEO Mo Trikha and Clinical Leader Executive Editor Abby Proch In acrowded antibody-drug conjugate (ADC) landscape, differentiation hinges on improving the fundamentalrisk–benefit equation.
Proven oncology leader to advance next-generation ADC pipeline and drive clinical milestones SAN MATEO, CA – Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Mohit Trikha, Ph.D., as Chief Executive Officer. Dr. Trikha, who previously served as President and Chief Operating Officer, assumes the […]
– Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved tolerability – Next-generation CEACAM5 ADC KIVU-305 demonstrates potent preclinical activity and enhanced stability across colorectal and other solid tumor models SAN MATEO, CA — April 15, 2026 – Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to […]
Seasoned biopharma executive brings more than 25 years of business development and strategic partnership experience to support Kivu’s next phase of growth SAN MATEO, Calif.–(BUSINESS WIRE)–Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Brunilda Shtylla, as Chief Business Officer. Ms. Shtylla will lead corporate […]
–Receives Australian HREC Approval and CTN Clearance for First-in-Human Study SAN MATEO, Calif.–(BUSINESS WIRE)–Kivu Bioscience, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the presentation of new preclinical data for KIVU-305, its CEACAM5-targeted ADC, at World ADC London 2026. Kivu also announced another significant milestone with receipt of […]
SAN MATEO, Calif. – Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors. Dr. Hambleton is a highly experienced biotechnology executive with more than 25 years of leadership across clinical development, regulatory strategy, and company building, spanning […]
SAN MATEO, CA – January 12, 2026 – Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced that the first patient has been dosed in its Phase 1 clinical trial of KIVU-107, a next-generation PTK7-targeting ADC for patients with advanced solid tumors. “Dosing the first patient with KIVU-107 […]